ARTICLE | Product Development
China a priority for Novartis’ Narasimhan
Novartis CEO Narasimhan on the pharma’s plans in China, BD&L and reimbursement
December 21, 2019 12:15 AM UTC
Novartis CEO Vasant Narasimhan says capitalizing on the rise of China, by prioritizing drug launches in the country, will be a key pillar of the pharma’s strategy over the next few years.
A second pillar will be M&A that builds depth in Novartis’ core therapeutic areas. ...
BCIQ Company Profiles